Form 4: Anterix CLO Gena Ashe Receives Equity Grant
Statement of Changes in Beneficial Ownership
Anterix Inc. Chief Legal Officer Gena L. Ashe was granted 3,694 restricted stock units and 17,453 stock options.
Summary
- Gena L. Ashe, Chief Legal Officer and Corporate Secretary of Anterix Inc., received an equity compensation package on May 20, 2026.
- The grant includes 3,694 restricted stock units (RSUs), each representing a right to one share of common stock.
- The grant also includes 17,453 stock options with an exercise price of $60.90.
- Both the RSUs and stock options follow a three-year vesting schedule, beginning May 20, 2027, with quarterly vesting thereafter through May 20, 2029.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation with no material impact on the company's operational strategy.
Positives
- Equity-based compensation aligns the interests of the Chief Legal Officer with long-term shareholder value.
- The multi-year vesting schedule serves as a retention mechanism for key executive talent.
Negatives
- The issuance of new equity awards results in potential dilution for existing shareholders.
Risks
- Future share price volatility may impact the ultimate value realized by the executive from these grants.
- The company remains subject to market risks that could affect the exercise value of the granted options.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on executive compensation disclosure.
Industry Context
StockSavvy.ai notes that equity grants for C-suite executives are standard corporate governance practices intended to incentivize long-term performance and retention in the technology and telecommunications sectors.
Comparison to Industry Standards
- The three-year vesting schedule is consistent with standard industry practices for executive compensation packages.
- The use of both RSUs and stock options is a common structure for aligning executive incentives with shareholder interests among mid-cap technology firms.
Stakeholder Impact
- Shareholders may experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of the first tranche of equity on May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of the equity grant transaction. |
| 05/22/2026 | Date of filing the Form 4. |
| 05/20/2027 | Initial vesting date for RSUs and stock options. |
| 05/20/2029 | Final vesting date for the equity grants. |
| 05/20/2036 | Expiration date for the stock options. |
Keywords
Anterix, ATEX, Insider Trading, Form 4, Executive Compensation, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.